These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 28358432)
1. iRGD as a tumor‑penetrating peptide for cancer therapy (Review). Yin H; Yang J; Zhang Q; Yang J; Wang H; Xu J; Zheng J Mol Med Rep; 2017 May; 15(5):2925-2930. PubMed ID: 28358432 [TBL] [Abstract][Full Text] [Related]
2. Tumor penetrability and anti-angiogenesis using iRGD-mediated delivery of doxorubicin-polymer conjugates. Wang K; Zhang X; Liu Y; Liu C; Jiang B; Jiang Y Biomaterials; 2014 Oct; 35(30):8735-47. PubMed ID: 25023394 [TBL] [Abstract][Full Text] [Related]
3. Cancer therapy with iRGD as a tumor-penetrating peptide. Thirumalai A; Girigoswami K; Pallavi P; Harini K; Gowtham P; Girigoswami A Bull Cancer; 2023 Dec; 110(12):1288-1300. PubMed ID: 37813754 [TBL] [Abstract][Full Text] [Related]
4. Recent advances in the tumor-penetrating peptide internalizing RGD for cancer treatment and diagnosis. Qian J; Zhou S; Lin P; Lei J; Zheng S; Xu W; Wang Y; Gao Z; Yang J Drug Dev Res; 2023 Jun; 84(4):654-670. PubMed ID: 36959702 [TBL] [Abstract][Full Text] [Related]
5. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer. Peng ZH; Kopeček J J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409 [TBL] [Abstract][Full Text] [Related]
6. Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy. Deng C; Jia M; Wei G; Tan T; Fu Y; Gao H; Sun X; Zhang Q; Gong T; Zhang Z Mol Pharm; 2017 Jan; 14(1):296-309. PubMed ID: 27936775 [TBL] [Abstract][Full Text] [Related]
7. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma. Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248 [TBL] [Abstract][Full Text] [Related]
8. iRGD-targeted delivery of a pro-apoptotic peptide activated by cathepsin B inhibits tumor growth and metastasis in mice. Qifan W; Fen N; Ying X; Xinwei F; Jun D; Ge Z Tumour Biol; 2016 Aug; 37(8):10643-52. PubMed ID: 26867766 [TBL] [Abstract][Full Text] [Related]
9. Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation. Hu C; Huang Y; Chen Y Mol Pharm; 2019 Feb; 16(2):561-572. PubMed ID: 30592418 [TBL] [Abstract][Full Text] [Related]
10. iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers. Zuo H J Oncol; 2019; 2019():9367845. PubMed ID: 31346334 [TBL] [Abstract][Full Text] [Related]
11. A Novel Strategy through Combining iRGD Peptide with Tumor-Microenvironment-Responsive and Multistage Nanoparticles for Deep Tumor Penetration. Cun X; Chen J; Ruan S; Zhang L; Wan J; He Q; Gao H ACS Appl Mater Interfaces; 2015 Dec; 7(49):27458-66. PubMed ID: 26633260 [TBL] [Abstract][Full Text] [Related]
12. iRGD peptide as effective transporter of CuInZnxS2+x quantum dots into human cancer cells. Przysiecka Ł; Michalska M; Nowaczyk G; Peplińska B; Jesionowski T; Schneider R; Jurga S Colloids Surf B Biointerfaces; 2016 Oct; 146():9-18. PubMed ID: 27244046 [TBL] [Abstract][Full Text] [Related]
13. Tumor-penetrating peptide fused EGFR single-domain antibody enhances cancer drug penetration into 3D multicellular spheroids and facilitates effective gastric cancer therapy. Sha H; Zou Z; Xin K; Bian X; Cai X; Lu W; Chen J; Chen G; Huang L; Blair AM; Cao P; Liu B J Control Release; 2015 Feb; 200():188-200. PubMed ID: 25553823 [TBL] [Abstract][Full Text] [Related]
14. iRGD-conjugated DSPE-PEG2000 nanomicelles for targeted delivery of salinomycin for treatment of both liver cancer cells and cancer stem cells. Mao X; Liu J; Gong Z; Zhang H; Lu Y; Zou H; Yu Y; Chen Y; Sun Z; Li W; Li B; Gao J; Zhong Y Nanomedicine (Lond); 2015; 10(17):2677-95. PubMed ID: 26355733 [TBL] [Abstract][Full Text] [Related]
16. Tumor Penetrating Peptide-Functionalized Tenascin-C Antibody for Glioblastoma Targeting. Lingasamy P; Laarmann AH; Teesalu T Curr Cancer Drug Targets; 2021; 21(1):70-79. PubMed ID: 33001014 [TBL] [Abstract][Full Text] [Related]
17. A tumor-penetrating peptide enhances circulation-independent targeting of peritoneal carcinomatosis. Sugahara KN; Scodeller P; Braun GB; de Mendoza TH; Yamazaki CM; Kluger MD; Kitayama J; Alvarez E; Howell SB; Teesalu T; Ruoslahti E; Lowy AM J Control Release; 2015 Aug; 212():59-69. PubMed ID: 26071630 [TBL] [Abstract][Full Text] [Related]
18. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Sugahara KN; Teesalu T; Karmali PP; Kotamraju VR; Agemy L; Girard OM; Hanahan D; Mattrey RF; Ruoslahti E Cancer Cell; 2009 Dec; 16(6):510-20. PubMed ID: 19962669 [TBL] [Abstract][Full Text] [Related]
19. [Physicochemical Property of iRGD Peptide Modified Doxorubicin Loaded Liposome and Its Effect on Cancer Cell Growth]. Zhang ZQ; Zhong CL; Zhao X Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Nov; 46(6):837-41. PubMed ID: 26867317 [TBL] [Abstract][Full Text] [Related]
20. Nanoparticles coated with the tumor-penetrating peptide iRGD reduce experimental breast cancer metastasis in the brain. Hamilton AM; Aidoudi-Ahmed S; Sharma S; Kotamraju VR; Foster PJ; Sugahara KN; Ruoslahti E; Rutt BK J Mol Med (Berl); 2015 Sep; 93(9):991-1001. PubMed ID: 25869026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]